Dermatologic Toxicities Associated with Anticancer Treatments
Approximately what percent of your patients receiving the following anticancer agents experience dermatologic side effects? (Median)
A 48-year-old man is receiving irinotecan/cetuximab as third-line treatment for metastatic colorectal cancer and is responding to therapy. He is due for his fourth week of treatment but presents with a Grade II acneiform rash (macular or papular eruption or erythema without associated symptoms).
A 48-year-old man is receiving irinotecan/cetuximab as third-line treatment for metastatic colorectal cancer and is responding to therapy. He is due for his fourth week of treatment but presents with a Grade II acneiform rash (macular or papular eruption or erythema without associated symptoms).
A 48-year-old man is receiving irinotecan/cetuximab as third-line treatment for metastatic colorectal cancer and is responding to therapy. He is due for his fourth week of treatment but presents with a Grade II acneiform rash (macular or papular eruption or erythema without associated symptoms).
Which of the following dermatologic side effects of EGFR inhibitors have your patients experienced? (Check all that apply)
How do you generally treat patients who present with significant rash secondary to treatment with erlotinib or cetuximab? (Check all that apply)
Which of the following dermatologic toxicities from the multitargeted tyrosine kinase inhibitors sorafenib and sunitinib do your patients...
For a patient with hand-foot syndrome due to treatment with sorafenib or sunitinib, which of the following medications would you most likely recommend to manage this side effect?
